Tracer	System	Parameters Measured	Results	Reference
Iopamidol (Isovue)	Rectal tumors	Perfusion and mean transit time	Decreased perfusion and increased mean transit time post-treatment; high perfusion index and short MTT index poor response to therapy.	[80]
Iomeron (Iomeprol)	Oropharyngeal and oral tumors	Permeability, blood flow, volume and mean transit time	All parameters elevated in tumors compared to normal tissue except for low mean transit times; differentiation between primary and recurrent tumors based on blood flow	[81]
Iodinated contrast agent	Head and neck tumors	Permeability, blood flow, blood volume and mean transit time	All parameters were significantly different in tumors compared to normal tissue	[82]
Iopamidol (Isovue 300)	Hepatic metastases	Perfusion	Perfusion elevated in metastases compared to contralateral tissue; significant correlation between survival and perfusion of metastasis (higher perfusion, increased survival)	[83]
Iopamidol (Isovue 300)	Lymphoma	Perfusion and permeability	Perfusion correlated well with grade and activity but permeability did not reliably differentiate between grade or activity	[84]
Iobitridol (Xenetix 30)	Non-small cell lung cancer	Perfusion, permeability and blood volume	Reproducibility of whole tumor perfusion both parameters was acceptable	[85]
Iopamidol (Niopam 340)	Colorectal tumors	Blood volume, blood flow, mean transit time and permeability	Correlation coefficients for interobserver variability and intraobserver variability indicated excellent agreement in both cases	[86]
Iopamidol (Niopam 340)	Colorectal tumors	Perfusion	Early changes in perfusion of tumors responding to bevacizumab demonstrated	[88]
Iodinated contrast agent	Advanced solid tumors refractory to therapy	Blood flow, blood volume, permeability and mean transit time	Phase I dose-escalation study of MEDI-522; only mean transit time demonstrated significant changes post- treatment	[89]